Financials data is unavailable for this security.
View more
Year on year net income at Biogaia AB changed little (from 373.77m to 365.35m) despite revenues that grew 17.44%.
| Gross margin | 73.59% |
|---|---|
| Net profit margin | 24.85% |
| Operating margin | 29.54% |
| Return on assets | 16.00% |
|---|---|
| Return on equity | 18.69% |
| Return on investment | 17.73% |
More ▼
Cash flow in SEKView more
In 2023, Biogaia AB did not generate a significant amount of cash. However, the company earned 425.97m from its operations for a Cash Flow Margin of 32.85%. In addition the company used 50.94m on investing activities and also paid 308.42m in financing cash flows.
| Cash flow per share | 4.04 |
|---|---|
| Price/Cash flow per share | 25.39 |
| Book value per share | 16.01 |
|---|---|
| Tangible book value per share | 14.42 |
More ▼
Balance sheet in SEKView more
| Current ratio | 7.78 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in SEK
Year on year, growth in dividends per share increased 137.93% while earnings per share excluding extraordinary items fell by -2.25%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
| Div yield(5 year avg) | 2.96% |
|---|---|
| Div growth rate (5 year) | 28.10% |
| Payout ratio (TTM) | 206.87% |
| EPS growth(5 years) | 7.85 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -23.02 |
More ▼
